Introduction
Millions of people are bitten by animals and some become infected with serious complications. 1 Infected dog and cat bite wounds grow pathogenic bacteria that include a wide variety of fastidious aerobic bacteria and approximately 50-80% grow anaerobic veterinary species. 2 Many laboratories are unable to isolate and/or identify this plethora of organisms, since many of these species are phenotypically similar to each other and others grow slowly and may be missed unless plates are incubated for a long time. Others may grow only if enriched media are used. In-vitro susceptibility studies of these unusual isolates are often not performed due to technical factors or cost constraints. Consequently, the clinician must often rely on published studies to guide both empirical and subsequent specific antimicrobial therapeutic choices.
Trovafloxacin is a new fluoroquinolone with aerobic activity and enhanced anaerobic activity 3, 4 that could make it useful for treating bite-wound infections. In order to determine its activity against a large variety of these pathogenic species, the susceptibility of 387 recent clinical human and animal bite-wound isolates to trovafloxacin was compared with that to other agents.
Materials and methods
The bacteria had previously been isolated from bite wounds and identified by standard criteria. 5, 6 The sources of the bites were dog (153), cat (159), human (46), squirrel (2), monkey (2) and pig (1) , and other or unknown animal origin (10) . Ten ATCC strains were also tested. The numbers and species of isolates tested are given in the Table. Standard laboratory powders were supplied as follows: trovafloxacin and azithromycin, Pfizer Inc., New York, NY, USA; ciprofloxacin, Bayer Inc., West Haven, CT, USA; ofloxacin and levofloxacin, R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA; clarithromycin, Abbott Pharmaceuticals Inc., North Chicago, IL, USA.
Frozen cultures were transferred twice on TSA agar supplemented with 5% sheep blood or chocolate agar for the aerobes and brucella agar supplemented with haemin, vitamin K 1 and 5% sheep blood for the anaerobes. Porphyromonas spp. and Moraxella lacunata ATCC 17967 were tested simultaneously with the appropriate plates and environments. The MIC was defined as the lowest concentration of an agent that yielded no growth, or a marked change in the appearance of growth as compared with the growth control plate.
Results and discussion
The activity of trovafloxacin and the other agents against the bite-wound isolates tested is compared in the Table. Previous susceptibility studies of new and older compounds 9 did not differentiate many of the newly identified Pasteurella spp. 5 and subspecies nor the Prevotella and Porphyromonas spp. isolated from these wounds 10 and therefore scant data are available to the clinician upon which to base selection of empirical therapy.
All four fluoroquinolones tested were active against the aerobic strains tested but trovafloxacin was more active against anaerobes. Trovafloxacin was active at 0.5 mg/L for aerobes and 2.0 mg/L for anaerobes except the fusobacteria (MIC 90 4 mg/L). Wexler et al. 4 reported on the activity of trovafloxacin against 557 anaerobes and Spangler et al. 3 on 489 anaerobes, but these studies did not include many of the species studied in this report. Wexler et al. 4 and Spangler et al. 3 reported that Fusobacterium nucleatum had an MIC 90 of 0.5 mg/L and 0.25 mg/L, respectively, and that other Fusobacterium spp. had an MIC 90 of 0.5 mg/L and 1.0 mg/L, respectively, while in our study the MIC 90 s for F. nucleatum and other fusobacteria was 4 mg/L. As we used the same methods as Wexler et al. 4 , the reason for this disparity was unclear except that we studied veterinary isolates recovered from human infections while they used human isolates from other sources. Spangler et al. 3 used supplemented WilkinsChalgren agar which might account for some variation.
Of interest, the different Pasteurella spp. tested were all susceptible to all of the fluoroquinolones ( 0.1 mg/L), but differences were found between azithromycin (MIC 90 0.25 mg/L) and clarithromycin (MIC 90 4.0 mg/L) (Table) .
Trovafloxacin appears to have improved activity against the full spectrum of pathogens isolated from human and animal bite wounds and merits further clinical evaluation.
